glp 1 who should not take The GLP-1 Agonists and Obesity: How Diabetes Drugs are Changing Non-Diabetic Lives — tl;dr pharmacy INFOGRAPHIC: The Hidden Risks of

J Clin Endocrinol Metab 83(9):30783082 Kauffman RP, Baker VM, DiMarino P, Gimpel T, Castracane VD (2002) Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations

CONTRAINDICATIONS skin diseases at the treatment site pregnancy and lactation cancer unstable diabetes epilepsy diseases of the immune system blood disorders associated with excessive bleeding hypersensitivity or allergy to any component of the preparation SIDE EFFECTS Application of L-Carnitine may cause redness, swelling or slight bruising at the treatment site

A monitoring visit is scheduled at 4 weeks

A reduction in the Lantus dose may be required in patients with renal or hepatic impairment